ZA87560B - Compound for the manufacture of a therapeutic agent - Google Patents

Compound for the manufacture of a therapeutic agent

Info

Publication number
ZA87560B
ZA87560B ZA87560A ZA87560A ZA87560B ZA 87560 B ZA87560 B ZA 87560B ZA 87560 A ZA87560 A ZA 87560A ZA 87560 A ZA87560 A ZA 87560A ZA 87560 B ZA87560 B ZA 87560B
Authority
ZA
South Africa
Prior art keywords
manufacture
compound
therapeutic agent
treatment
conditions
Prior art date
Application number
ZA87560A
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Efamol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Ltd filed Critical Efamol Ltd
Publication of ZA87560B publication Critical patent/ZA87560B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA87560A 1986-01-27 1987-01-26 Compound for the manufacture of a therapeutic agent ZA87560B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868601915A GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA87560B true ZA87560B (en) 1987-09-30

Family

ID=10591997

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA87560A ZA87560B (en) 1986-01-27 1987-01-26 Compound for the manufacture of a therapeutic agent

Country Status (13)

Country Link
US (2) US4753964A (de)
EP (1) EP0234733B1 (de)
JP (1) JPS62185018A (de)
AT (1) ATE69378T1 (de)
AU (1) AU593317B2 (de)
DE (1) DE3774449D1 (de)
ES (1) ES2040242T3 (de)
GB (1) GB8601915D0 (de)
GR (1) GR3003120T3 (de)
HK (1) HK127893A (de)
IE (1) IE59606B1 (de)
SG (1) SG114293G (de)
ZA (1) ZA87560B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120763A (en) * 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
US5599840A (en) * 1986-11-26 1997-02-04 Bar Ilan University Physiologically active and nutritional composition
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
EP0289204B1 (de) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithiumsalze enthaltende pharmazeutische Zubereitungen
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4851398A (en) * 1987-09-30 1989-07-25 Elena Avram Bismuth containing pharmaceutical compositions
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
IL91802A (en) * 1988-10-27 1994-05-30 Univ Bar Ilan Preparations containing linoleic acid history for the treatment of Alzheimer's, similar brain diseases, and epilepsy
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
CA2101274C (en) * 1991-01-24 1998-12-15 David J. Kyle Microbial oil mixtures and uses thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0701441A1 (de) * 1993-06-01 1996-03-20 Cortex Pharmaceuticals, Inc. Inhibitoren basische und azide Phosphatase zur Behandlung neurologischer Krankheiten
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU1067795A (en) * 1993-11-26 1995-06-13 Karla Lehmann Use of lithium compounds in the treatment and prevention of alzheimer's disease
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
EP0726073A3 (de) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
CN1109543C (zh) * 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
JPH11279066A (ja) * 1998-03-25 1999-10-12 Mitsubishi Chemical Corp リチウム塩を有効成分とする神経細胞死抑制剤
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1888081B1 (de) * 2005-05-23 2016-12-28 Massachusetts Institute of Technology Zusammensetzungen mit pufa und anwendungsverfahren dafür
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
BRPI0621248A2 (pt) * 2006-01-17 2011-12-06 Majid Fotuhi medicamento e regime de dosagem para prevenção ou redução do risco de permanência ou progressão de demência através de administração de vitaminas especìficas e nsaid
MX2008012479A (es) * 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
EP2098229A4 (de) 2006-12-28 2010-03-10 Suntory Holdings Ltd Nervenregenerationsmittel
US20080181937A1 (en) * 2007-01-29 2008-07-31 Majid Fotuhi Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
KR101397554B1 (ko) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
BRPI1000970A2 (pt) 2010-04-07 2011-11-29 Fundacao Arnaldo Vieira De Carvalho composição farmacêutica para o tratamento da doença de alzheimer, processo para sua obtenção e uso
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2015147742A1 (en) * 2014-03-24 2015-10-01 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment
JP2016023163A (ja) * 2014-07-22 2016-02-08 出光興産株式会社 γ−リノレン酸を含む神経細胞の酸化ストレス軽減剤
RU2587617C1 (ru) * 2014-12-23 2016-06-20 Ольга Алексеевна Громова Способ профилактики и лечения нейродегенеративной патологии и сосудистой деменции
US9603869B2 (en) 2015-05-22 2017-03-28 University Of South Florida Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
EP3468550A4 (de) * 2016-06-13 2020-02-12 Syneurx International (Taiwan) Corp. Verwendung von lithiumbenzoat zur behandlung von störungen des zentralen nervensystems
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function
CA3141059A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels

Also Published As

Publication number Publication date
IE870194L (en) 1987-07-27
US4810497A (en) 1989-03-07
HK127893A (en) 1993-11-26
IE59606B1 (en) 1994-03-09
SG114293G (en) 1994-01-21
EP0234733B1 (de) 1991-11-13
AU593317B2 (en) 1990-02-08
AU6767587A (en) 1987-07-30
JPS62185018A (ja) 1987-08-13
US4753964A (en) 1988-06-28
ATE69378T1 (de) 1991-11-15
ES2040242T3 (es) 1993-10-16
DE3774449D1 (de) 1991-12-19
EP0234733A1 (de) 1987-09-02
GR3003120T3 (en) 1993-02-17
GB8601915D0 (en) 1986-03-05

Similar Documents

Publication Publication Date Title
ZA87560B (en) Compound for the manufacture of a therapeutic agent
HUT71889A (en) Pharmaceutical compositions containing terfenadine metabolites and their optically pure isomers for treating allergic disorders
CA2133998A1 (en) Treatment of macular degeneration
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE135909T1 (de) Verfahren zur behandlung von akne
EP0328634B1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis
IL90056A0 (en) Topical pharmaceutical compositions containing 4-quinoline carboxylic acid derivatives
KR950000141A (ko) 피부병 치료용 약제조성물 제조를 위한 방향족산을 함유한 l- 카르니틴 o-에스테르의 용도
DE2967356D1 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE69207479D1 (de) Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
DE69315162D1 (de) Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
IL103799A (en) Fish production
GR3006606T3 (de)
DE3467705D1 (en) Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine
DE3362246D1 (en) Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid, the process for its preparation, and therapeutic compositions which contain it as active principle
EP0383481A3 (de) Bukkale Anästhetika
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
JPH03251526A (ja) 糖尿病依存型自己免疫疾患治療、予防用薬剤
IL86647A0 (en) Pharmaceutical compositions comprising a naphthalene carboxylic acid derivative
RU93058599A (ru) Новые диметиламинооксиалкандифосфоновые кислоты и их соли, способ их получения, содержащие их фармацевтические составы, применение